We provided substantial evidence that soluble neuritin reverses the synaptic defects in an animal model of AD, suggesting that manipulating the level of endogenous neuritin or supplying exogenous soluble neuritin may offer therapeutic benefits against neurodegenerative diseases. This evidence concerns the gene NRN1 and Alzheimer disease.